Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB

Study Identifier:
NGLU-NH02
ClinicalTrials.gov Identifier:
NCT02293408
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
    Date
    Sep 2014 - Jul 2017
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: 1+ years
    Requirements Information
    Sex
    Female & Male
    Age
    1+ years

    Study Details

    Medical Condition
    • Unmapped
    Study Drug
      Date
      Sep 2014 - Jul 2017
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: 1+ years years
      Requirements Information

      Protocol Summary

      The objectives of this study are to describe the clinical and biochemical characteristics and course of disease progression in participants with Mucopolysaccharidosis type IIIB (MPS IIIB)

      Trial Locations

      Location
      Status
      Location
      Minneapolis, Minnesota, United States
      Status
      N/A
      Location
      Pittsburgh, Pennsylvania, United States
      Status
      N/A
      Location
      Porto Alegre, Brazil
      Status
      N/A
      Location
      Monza, Italy
      Status
      N/A
      Location
      Coimbra, Portugal
      Status
      N/A
      Location
      Barcelona, Spain
      Status
      N/A